About Aldurazyme®

Prior to the introduction of enzyme replacement therapy (ERT), the major focus of MPS I management was supportive care. Although these measures still have a place in the management of MPS I, enzyme replacement therapy with Aldurazyme® (laronidase) is now an option for patients with a confirmed diagnosis of Mucopolysaccharidosis I (MPS I; alpha-L-iduronidase deficiency) to treat the non-neurological manifestations of the disease.^[1]

Aldurazyme reverses the accumulation of glycosaminoglycans (GAG), which is the underlying cause of MPS I.^{[1, 2]}

Please see the full prescribing information in Dutch or in French (PDF) for Aldurazyme^®.

For more information on the criteria for reimbursement of Aldurazyme^® in Belgium, see RIZIV/INAMI reimbursement criteria for Aldurazyme®

To access information about the steps required to reconstitute and administer Aldurazyme^® see Reconstitution and Administration.

References

1. Summary of Product Characteristics Aldurazyme®

2. Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Eng J Med. 2001;344:182–188.